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Abstract: To assess the quality of centrally prepared
cytotoxics a global approach is being implemented by
pharmacists. A risk analysis is performed, and then
many in-process controls are proposed. The aseptic pro-
cess and the material are also fully validated. Moreover
the skills of pharmacy technicians are being checked and
monitored over time. This short opinion paper discusses
the place of in-process quality control within the quality
system applied to cytotoxic preparations. It also dis-
cusses the pros and cons of analytical control of the
final product versus continuous control of each prepara-
tion step by eye witness or an electronic device such as a
camcorder. Finally the relevancy of controls is discussed
in function of different cases and of the human and
material resources available in the pharmaceutical tech-
nology cytotoxic unit.
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Nowadays, chemotherapies are prepared by pharmacy
technicians in centralized production units under the
responsibility of the pharmacists. These products have
specific characteristics. First, they are sterile and are
thus prepared using an aseptic processing method.
Second, their therapeutic margins are often narrow and
their toxicity is high. This is why they are prescribed
following validated schedules with body-surface calcu-
lated doses in most cases. Third, the prescription is
usually adapted by taking into account the last biological
results of the patient and his or her health status at the
time of injection. Thus, the delay between prescription
and injection is as short as possible. From the three
characteristics above, it is easy to understand that che-
motherapy compounding is a risky business.
In Spain, during the year 1993, a pharmacist team
evaluated an overall rate of 6.63% errors (0.33% per con-
trolled parameter) on cytostatic preparations by tracing 20
check points going from the prescription to the administra-
tion of the drug to the patients [1]. If one looks only on the
error on the concentration of the drug in the drug product
the error rate was evaluated to 0.5% over a 7-years period
in an University Hospital in the east of France [2]. To lower
the risk as much as possible the production process is fully
validated: media fill tests are implemented to assess that
the process is aseptic and that the operators are qualified, a
quality insurance system is used and many controls are
implemented at each critical step, which are determined
using prospective risk analysis [3, 4].
In fact, the first controls consist to carefully check, at
time of arrival in stock, all the materials and drugs that will
be used for the compounding process. The biological safety
cabinets or the isolators are also qualified and daily con-
trolled by tracing some parameters such as pressure, air-
flow velocity, temperature and so on. During the production
of a prescribed product many check points are used such as
validity of the prescription, type of syringes, drug vials
identifications, date of use or identity of solvent.
Then comes the time of effective compounding and at
this step the pharmacists has two different choices. Either
to only control the final product or to follow each single
step of the compounding process by eye witness or an
electronic device such as a camcorder or a camera in
order to assure that there are no errors in the process and
finally that the right drug is given at the right dose in the
good vehicle. Finally other controls have to be implemen-
ted to check that the drug products is correctly labeled
(in order to be taken by the right patient) and that no
chemical incompatibilities and particles are present, these
last controls are performed by visual inspection (Figure 1).
Thus, a choice has to be made for the control procedure
during the compounding process: is it better to control the
final product by an analytical technique or to follow the
steps with eye witness or a camcorder? Some papers
already compare the different techniques used in these
two cases [5, 6], from those papers it is easy to understand
that no universal technical answer is proposed today.
*Corresponding author: Frederic Lagarce, MINT Inserm U1066,
CNRS 6021, University of Angers, Angers, France; Pharmacy
Department, Angers University Hospital, 49033 Angers cedex 9,
Angers, France, E-mail: Frederic.lagarce@univ-angers.fr
Pharm. Technol. Hosp. Pharm. 2017; 2(1): 29–33
Brought to you by | Université d'Angers
Authenticated
Download Date | 7/19/17 2:35 PM
This last decade showed big evolutions of the process of
sterile cytotoxic preparation in hospital using standar-
dized doses and more recently robotics both giving
great opportunities for securization of the process con-
trol. The most significant progress is the possibility of
suppressing in-process control by eye-checking by using
other more relevant methods such as in-process video
recording, gravimetric checks and final analytical control.
Different solutions are offered to hospital pharmacists to
improve control of the process of compounded prepara-
tion. This opinion paper attempts to present the control
methods used in hospital pharmacy production of cyto-
toxic sterile drugs and more generally injectable drugs,
while discussing their interests and limits.
Ultraviolet detection is mostly used in the group of
the analytical techniques applied to chemotherapy-qual-
ity control. Ultraviolet spectrometry can be performed
alone (Druglog® distributed by Pharmed) or associated
to Fourrier Transformed Infrared Spectrometry (FTIR)
which was called Multispec® or to Raman spectrometry
(QC Prep + ®, Icônes Services, France) [7]. Ultraviolet
detection was also used in quality controls by High
Pressure Liquid Chromatography (HPLC) coupled to a
diode array detector (DAD) [8]. Raman spectrometry has
also been proposed alone and has the major advantage to
determine the analyte without destruction through its
container and thus limiting chemical contaminations [9,
10]. The major problem of those analytical techniques is
that they are not able to detect and quantify all antic-
ancer drugs. Mass spectrometry would be able to deter-
mine all compounds but it had not been proposed yet
because it is time consuming and analytical skill to inter-
pret the data is higher. This is why other techniques such
as gravimetric control [11] have been implemented in
particular when robots are used to prepare cytotoxic
drugs. The specificity of this technique is however not
good enough if used alone. Finally cameras [12] or video
recording (Drugcam®, Eurekam, France) [13] have been
proposed to control all prepared chemotherapies without
enhanced risk of chemical contamination due to analyte
vial handling and no drug volume loss for analysis. These
two points are considered as major advantages of the
video system over the analytical procedure (excluding
raman analysis).
Each technique has its flows. Analytical techniques
can only be performed and validated by team having
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Figure 1: Types of controls implemented in cytotoxic preparation to assess the quality of the final product.
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skills in analytical chemistry; chemical contamination of
bench is possible; chemical analysis takes a few minutes
and this can be important for long series of prepared
products; false non conformity can occur if the drug is
not properly homogenized and finally the volume of the
analyte is destroyed and not injected to the patient even
if some analytical methods can be process with low sam-
ple volumes [14]. Analytical control has also the costs of
consumables (vials, columns, mobile phases, cleaning or
standard solutions) which vary from one technique to
another but is often over 1€ per sample, which can be
high for big chemotherapy centers.
On the other hand, visual controlled can be biased if
the attention of the watching person is not perfect, which
can occur after a few hours of work or if the worker is
worried by extra professional reasons or even stressed
during work this is why this technique is now replaced
by video recording. Actually, electronic visual control is
consistent during a full day of work but it cannot detect
what is not shown to the lens of the camera. In fact, if
every step of preparation shown in front of the camera
lens is correct the preparation will be validated but if by
mistake one additional wrong step is added without
showing it in front of the camera, the system may not
detect it. Moreover, electronic visual control does not
provide any accurate quantification on the drug concen-
tration and vehicle effectively present in formulation that
will be injected to the patient. In fact, it can only be
postulated that if every preparation step is correct, the
concentration and vehicle will be very close to the
awaited value but assuming the good quality of the raw
material used. Actually, a video recording will not be
accepted as a mean to quantify a concentration with a
validated standard error according to International
Conference of Harmonization (ICH) guidelines on valida-
tion of analytical procedure (ICH Q2).
From the text above, one can assess that in-process
controls or final analytical control do no give the same
amount of information. This is why each pharmacist has
to decide what level of information he needs to assure the
quality of the prepared drugs. At the end he is the respon-
sible person who will have to justify his choices in case of
quality check by external inspectors. In fact, dosing the
drug and vehicle by HPLC-DAD, raman spectroscopy, near
infrared spectrometry or other techniques gives more infor-
mation than just checking the steps of the production pro-
cedure. For example if the quality of the drug or vehicle
provided by the pharmaceutical industry is not good, this
can be detected by a final dosing of the prepared che-
motherapy. But is it the responsibility of the hospital phar-
macist to re-check what has already been released after
many controls in the pharmaceutical industry? In the past
a batch was withdrawn from the market after a quality
control performed by a compounding hospital pharmacy
[15]. Dosing the final product allows also to waive the
responsibility of the pharmacist in case of a bad clinical
outcome after injection of the chemotherapy. In our hospi-
tal, a few toxic outcomes related to methotrexate too high
area-under-plasma-concentration versus time curve (AUC)
were observed. Because our preparations were dosed by
combined FTIR/UV (Multispec®/Microdom, France), we
could prove that the quality of the product prepared by
the pharmacy could not be doubted. Thus the high AUC
was more related to a pharmacokinetic parameter such as a
defect of elimination by the patient.
So can we say that bigger is better and that analytical
control should be implemented instead of electronic visual
control ? Not easily because as said before it requires a good
expertise, time, consumables and can lead to chemical con-
tamination of the analytical work bench. It could also be
raised that a badly performed or non-fully validated analy-
tical control could give a false green light for the release of
the product to the medical wards. The risk of misuse for
electronic eye control is much lower as it is much more
simpler to understand and to validate. So every responsible
pharmacist has to decide if the game is worth the candle, in
function of the personal he has, his budget, his expertise in
analytical chemistry, the type of chemotherapies he often
produces, the quantity of products prepared daily.
However one has to look carefully at the following
particular case. Standardized doses of cytotoxic drugs
(also called dose banding) have been proposed in order
to facilitate a rapid access to the treatment for patients
[16] and are now proposed by the National Health Service
in England [17]. In this case, series of cytotoxic prepara-
tion containing the same amount of drugs are prepared.
Thus an error on the concentration of the drug or an error
of drug (i. e. cisplatin used in place of carboplatin) can
lead to adverse effects in many patients. This is why we
think, that in this case, an analytical control should be
performed at least on some preparations from the same
batch. The time requested by the control is not a draw-
back because those preparations are produced in
advance. It is also important to note that in the case of
preparation performed in series, a microbiological stabi-
lity test or an integrity test should be performed to vali-
date the shelf life of those products.
We thus can propose a first answer to the question
raised in the title of this paper: the purpose of quality
control is to keep the overall risk at an acceptable level. It
should be underlined here that tThe risk of errors in che-
motherapies is not restricted to the pharmacy department
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and can be very harmful to the patient [18]. A global
approach has thus to be implemented to reduce the risk
and enhance the patient safety as much as possible.
A second main reason to perform a quality control
is to provide evidence of the quality of the product at
the time and in the physical conditions it is released by
the responsible pharmacist to the oncology units. To
release the product, the pharmacist needs to review all
the data from the preparation and to visually check
the aspect of the cytotoxic drug. At this step the phar-
macist needs some data supporting the quality of the
product. Traceability of the process by eye-witness or a
camcorder is very useful in this purpose. Camcorder
also called electronic eye is the best choice as it is
reliable and allows to check all types of preparations
including now clinical trials. In the last software ver-
sions designed for camcorder controls, the analysis of
the video is automatized and the software is validated
to check the volumes in syringes according to the pre-
paration protocol.
Finally the purpose of quality control is also to con-
tribute to a databank used to investigate in case of bad
clinical in patients. In this last case, for the reason
explained above, analytical control is superior to archive
video recordings because the concentration of the active
drugs is effectively determined in the final product with a
validated and known accuracy. However, in case of
inquiry the video archives could be very useful if a second
determination of the concentration cannot be performed
for example for stability issues or because a sufficient
volume of the remaining sample is not available.
As a conclusion, we can say that in-process con-
trols, especially video control, which is reliable and
allows archiving, are a complement to analytical control
of the final product. In function of the level of informa-
tion he needs, the responsible pharmacist will have to
choose between these techniques or associate them. The
best way to implement a relevant strategy of quality
control is to perform a risk analysis taking into account
the local conditions of preparation (i. e. quantity, iden-
tity of drugs, target patients …) and then to decide in
function of local expertise and budget. This risk analysis
will be documented and can be discussed if the process
is audited. As a bottom line we want to emphasize that
the field of cytotoxic preparation and its associated
technology is greatly evolving. This means that what
may be relevant today may not be in the next years.
As an evidence of this, it is worth to note that automa-
tion is now proposed by several providers to prepare
cytotoxics. In this case a gravimetric control is
embedded in the process. The average dose error was
evaluated to be around 1% with those systems, which
limit human errors in many preparation steps [19].
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